DexCom Posts $275.1M Third-Quarter Net Income
DXCM sits 48% above its 52-week low of $54.11.
Summary
DexCom reported third-quarter net income of $275.1 million, with revenue of $1.34 billion, up 11% year over year, and EPS of 72 cents. The company raised its 2026 revenue guidance to $5.20-$5.25 billion (12-13% growth), with non-GAAP operating margin about 24% and adjusted EBITDA margin about 32%, and authorized a $1 billion buyback. The result lands after a positive stretch for the stock, including the October 15 CONNECT trial publication in the New England Journal of Medicine showing the G7 CGM cut A1C.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Dexcom raised 2026 revenue guidance to $5.20-$5.25 billion (12-13% growth), with non-GAAP operating margin about 24% and adjusted EBITDA margin about 32%.
At the time of this announcement, DXCM was trading at $79.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.2B. The 52-week trading range was $54.11 to $92.59. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.